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Beta-endorphln and Running Add ¼tlon: Use In 
The Treatment of Schizophrenia, Mania, 
Depression and Anxiety 
Distance Running 
Recent history has witnessed a resurgence Tn the sport 
of distance running. Ken Young, the director of the Nation-
al Running Data Center, noted that In 1977 approximately 
~5,000 runners completed marathons, an Increase of 40 % over 
the 1976 figure ( Slovlc, 1978 ) . The Increased popularity of 
running l s r eflected In the numerous popular ma gazine s 
devoted to running. One major aspect of running dealt with 
by these magazines Is the positive benefits of running. 
William Glasser (1976) surveyed runners who subscribed 
to Runner ' s World magazine. He hypot hes I zed a "Pos It Ive 
Addiction (PA ) state" which consisted of euphoric feel lngs, 
occasional flashes of Insight, and heightened awareness of 
the environment In runners who could run for one hour 
without undue fatigue. Glasser cataloged physiological and 
psychological 
running. 
effects from running and abstinence from 
Bortz C 1 9 8 2 ) , a 1 so I n Run n e r ' s Wo r l d , s umm a r l zed t he 
research on the euphoric feel Ing s and heightened awareness 
of runners. He Indicated a possible physiological mechanism 
to account for the "runner's high", I.e., "PA state". 
Beta-endorphln, an endogenous opiate similar to morphine Is 
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produced In the body in response to extreme physical exer-
tion. Blood samples drawn from runners have Indicated that 
Beta-endorph In product I on began short 1 y after runn Ing was 
Initiated, lasted throughout the run, and ended a short time 
after running ceased. 
In summary, Increased numbers of peop 1 e a re engaged In 
distance running. According to popular 1 lterature these 
runners experience profound physiological and psychological 
effects, possibly due to Beta-endorphln. 
Problem Statement and Ouestlons 
Neither Glasser's (1976) survey data nor popular 
magazine articles (which seldom cite references) have 
provided conclusive evidence regarding the existence of 
running addiction or establ I shed causal lty between this 
addiction and Beta-endorphln. An Integration and summariza-
tion of research on the effects of opiates., Beta-endorphln 
and running will answer the following question, or Indicate 
where evidence Is Insufficient and explore avenues that 
require further research. 
Question 1: Is distance running addictive and If 
so, what is the role of Beta-endorphln In this 
addiction? 
Secondly, prior reviews of research of the effects of 
opiates and Beta-endorphln on psychopathologlcal Illnesses 
wl 11 be combined with research on both running as a thera-
peut lc tool and Its Impact on personal lty. An Integration 
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and summary of the research In these areas wl 11 answer the 
following question, or Indicate where evidence Is not 
sufficient plus explore areas for additional research. 
Question 2: What lmpl !cations would running-
produced Beta-endorphln have for therapy? 
Methods 
Data was gathered on 5x8 notecards. Where possible 
prior reviews were utll !zed, though In some areas the orig!-
nal reports of findings were reviewed. Where discrepancies 
exist between prior reviews, methodological and other 
rationale were explored for an explanation. Notecards for 
data from original research, when util !zed, contained; 
sample size, sample composition, methods, results, discus-
sion, and conclusions. 
Definition of Terms 
Addiction: The state In which both dependence and 
the posslbil lty of withdrawal exist 
(Randels, Mccurdy, Powell, Kilpatrick, 
Keeler, 1974). 
Aerobic: In the presence of oxygen (Taber, 1965). 
Agonlst: A drug which occupies a binding site, 
does have effects, and Is blocked by an 
antagonist drug (Randels et al., 1974). 
Cross-tolerance: If tolerance to drug A appl Jes to drug B 
on the first use (Randels et al., 1974). 
Dependence: If a person uses a drug and feels a need 
for It (Randels et al., 1974). 
Endogenous: Produced within the organism (Taber, 
1965). 
Morphine: Main alkaloid found In oplum ... wldely 
Opiate: 
\A! I thdrawa 1 
Symptoms: 
Tolerance: 
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used as analgesic and sedative ( Taber, 
1965). 
A drug derived from opium, which Is habit 
forming (Taber, 1965). 
Restlessness, depression and mild disturb-
ances In functioning of the autonomic 
nervous system (Taber, 1965). 
Need for greater amounts of a drug to 
cause the reaction originally obtained 
with a smaller dose (Randels et al., 
1974). 
Addiction and Running 
Oplolds and Beta-endorphin 
Research History. Bunney, Pert, Klee, Costa, Pert, and 
Davis (1979) and Verebey, Volavka, and Clouet (1978) re-
viewed the endogenous opioid research which resulted In 
Identification of Beta-endorphln. Bunney, In Bunney et a 1 . 
(1979), dates the beginnings of the research as 1973. Three 
Independent laboratories (Pert, Pasternak, & Snyder, 1973; 
Simon, Heller, & Edelman, 1973; Terenlus, 1973) almost 
simultaneously discovered the existence of specific opioid 
neurotransmitter sites In rat brain tissue. Hughes, Smith, 
Kosterl ltz, Fotnergel l, Morgan, and Morris (1975) provided 
the second advance with the Identification of two endogenous 
opioid peptides In the brains of pigs. They we re named 
Met-enkephal In and Leu-enkephal In. Met-enkephal In (Beta-
LPN,61-65) was recognized by these Investigators as an amino 
acid sequence of a larger peptide hormone of the anterior 
pituitary gland (Beta-1 lpotropln I • e. , Beta-LPH, 1-91) 
Identified by LI In 1964. 
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Goldstein (1976) was the first to find endorphins In 
the pituitary that also had opioid activity. 
Beta-endorphin, (Beta-LPH, 61-91) was Isolated ~rom the 
pituitary of camels by LI and Chung (1976). LI, Chung, and 
Doneen (1976) then Isolated Beta-endorphln from human 
pituitary glands. Ut I l lzlng radio Immunoassay Terenlus, 
Wahlstrom, and Johansson (1979) also found Beta-endorphln In 
human cerebrosplnal fluid (CSF) while Wardlaw and Frantz 
(1979) confirmed Beta-endorphln's presence In human plasma. 
Analgesia and Addiction. Endorphins have been shown to 
produce analgesia In rats (Bloom, Segal, Ling, & Gulllemln, 
1976; Graf, Rona!, Rajusz, Cseh, & Szekely, 1976. Beta-
endorphln was determined to possess significant opiate 
agonlst activity (LI et al., 1976). Loh, Tseng, Wei, and LI 
0976 ) est !mated that It was 18-33 t Imes more potent than 
morphine as an analgesic. 
Chronic administration of Met-enkephal In Into the 
perlaqueductal gray matter of rodent brains resulted In 
tole ranee to enkepha l In and morph I ne as we 11 as na l oxone 
(opioid antagonist) Induced withdrawal symptoms (Wei & Loh, 
1976). Van Ree and de Weld (1981) demonstrated cross-
tolerance between Beta-endorphln and morphine as well as the 
similarity In the development of tolerance and physical 
dependence. 
(van Ree, 
Two studies with rats by van Ree and associates 
Dorsa, & Colpaert, 1978; van Ree, Smith, & 
Colpaert, 19 7 9) demonstrated that Beta-endorph In p reduced 
abuse In rats similar to heroin abuse. Vereby et al. (1978) 
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states in summary that "this pept I de possesses a 11 of the 
choracterlstlcs of morphlne-1 Ike drugs" (p. 878 ) . 
Endogenous Opiate System. Wamsley (Note 1) provided an 
overview of the endogenous opioid system and l lkely Influ-
ences. He reported that Beta-endorph In and Met- and Leu-
enkepha l In are contained In separate neuronal systems In the 
brain where they act as neurotransmitters. Beta-endorphln 
may also be a circulating opioid and can last for a couple 
of hours In peripheral circulation before being destroyed. 
Enkephal Ins and endorphins are located In neuronal systems 
which Influence noclceptlon (pain ) and 
receptors nre located In regions of the 
behavior. Their 
bra i n known to 
Influence respiration., sleep., plus affect mood., and blood 
pressure. 
Pert., In her review of endogenous opiate systems 
(Bunney et al . ., 1979) reports that research with rats does 
suggest that brain opiate receptor occupancy by endogenous 
opiates Is Increased 
1979; Chance., White., 
research wl th rats 
after stress and pain 
Krynoc k., 
confirmed 
& Rosecrans, 
(Pert & 
1978). 
Bowie., 
Al so., 
that the pituitary releases 
Beta-endorphln Into the blood after acute stress and pain 
(Rossler., French., Rlvler., Ling., Gulllemln., & Bloom., 1977). 
Summary. Infra-human research on oplolds and Beta-
endorphln confirms that Beta-endorphln Is an endogenous 
opioid with powerful analgesic as well as addictive proper-
ties. With acute stress and pain Beta-endorphln Is released 
from the pituitary gland Into the blood and shows Increased 
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occupation of brain opiate receptors. Beta-endorphln Is 
located in neuronal systems which may Influence pain percep-
tion and Its receptors are located In brain regions which 
may affect mood. Beta-endorphin has been Identified In 
human pituitary glands, cerebrosplnal 
plasma. 
Opioid Addiction and Running Addiction 
fluid, and blood 
Opioid Addiction. Medical l lterature describes the 
effects on humans of opiates, Inclusive of Its derivative 
morph I n e (Tab e r, 1 9 6 5 ) . Morph I n e effects I n c l u de e up ho r i a 
and analgesia . With chronic use tolerance, dependence, and 
addiction 
abstinence 
occur (Rande 1 s 
symptoms occur 
et 
when 
al . , 1974). 
opiates are 
Withdrawal or 
abruptly with-
drawn (Kolb, 1977). They Include autonomic, central nervous 
(CNS), and musculo-skeletal symptoms. Autonomic symptoms 
Include; runny nose, teary eyes, flushed face, perspiration, 
nausea, vomiting, diarrhea, and loss of appetite. Cf\lS and 
musculo-skeletal symptoms Include; bone and muscle aches, 
muscle spasms and twitches (Randels et al., 1974). Addi-
tlonal symptoms from Kolb (1977) Include; restlessness, 
pessimism, surl lness, Insomnia, Irritability, Increased 
heart rate, and feel lngs of weakness. 
Running Addiction. Chan (1981), In her review of 
running as an addiction, began with Will lam Glasser's (1976) 
hypothesized "Positive Addictive or PA state". The "PA 
state" consisted of euphoric feel lngs (author's emphasis) ... 
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achieved by runners who could run daily for 40 minutes to an 
hour without undue fatigue after 
Glasser reported the results of 
approximately one year. 
a survey of runners who 
subsc r I bed to Runner's Wor 1 d magaz I ne. He described the 
pos It Ive effects of runn Ing and the negat Ive effects of 
abstinence from runn Ing. G 1 asser' s 1 I st of pos It i ve bene-
f I ts consisted of; a sense of well-being (author's empha-
sis), Increased self-confidence, decreased hostll lty, 
reduced anxiety, mental alertness, Increased energy, In-
creased self-awareness, reduced heart rate, weight control, 
and reduced proneness to Infections. Runners who abstained 
from running reported that they suffered from; lrrltabll lty, 
Insomnia , stomach upset , apathy, mental and physical slug-
g I shness (author's emphas Is), decreased se 1 f-esteem, head-
aches, and weight loss. Morgan (1979) also considered 
running as an addiction but focused on the negative aspects, 
stating that, "a hard-core exercise addict can't 1 Ive 
without dally running and manifests withdrawal symptoms if 
deprived of exercise" (p. 57). He reported that running 
produced the sensation of feel Ing better and "exercise 
highs" (author's emphasis). Withdrawal symptoms Included; 
muscle tension and soreness, lrrltabl l lty, Insomnia, depres-
slon, 
anxiety. 
restlessness, fatigue 
Morgan reports that 
(author's emphas Is), and 
he views "exercise addiction 
as no different than the addictive process in general" (p. 
60). 
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Jacobs (1981) also reviewed research on running as an 
addiction beginning with Glasser (1976). He Included 
several other studies which provided additional support for 
runn Ing add I ct I on. Little (1979), In a study of 72 male 
neurot le pat lents, reported that 39 percent were athletic 
personalties whose neurosis was precipitated by the shock of 
a threat to their physical prowess. He further reported 
that "athletic neurosis" was experienced with running 
abstinence and was characterized by depression (author's 
emphasis), and anxiety. Carmack and Martens 0979), In a 
study of 250 males and 65 female runners, Investigated 
commitment to running, average length of run, discomfort 
\ 
experienced when a run was m I ssed, pe rce I ved add I ct I on to 
running, and the states of mind which occur during the run. 
One result demonstrated that subjects running greater than 
40 minutes per session had a higher commitment to running 
than those running less than 40 minutes. Jacob's (1981) 
found this was supportive of the subjective evaluation by 
Kostrubala (1976) that 40 minutes of running were required 
for one to experience the "feel Ing good" (euphoric) stage of 
running. Jacob reported that "those runners experiencing 
discomfort were In actual lty evidencing withdrawal symptoms, 
which In turn were the classic Indicators that an addictive 
process was In place" (p. 79). 
Running and Analgesia. The reduct I on of pa In wh 11 e 
running has been examined In popular running 1 lterature. 
For example, Meisler (1984) suggested that after shorter, 
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hard runs (I.e. 6 miles at 85 % of maximum abll lty) or during 
longer runs of 12-15 miles, runners will likely become less 
sensitive to pain. 
Two studies provide support for the connection between 
Beta-endorphln, analgesia, and running. Von Knorr Ing, 
Alrnay, Johansson, and Terenlus (1978) found elevated levels 
of Beta-endorphln In the cerebrosplnal fluid (CSF) of 45 
patients with chronic pain syndrome. They concluded that 
patients with high endorphln levels have higher pain thres-
holds and pain tolerance. Janal, Colt, Clark, and Glusman 
(1984) tested 12 long - distance runners on thermal, lschemlc, 
and cold pressor pain tests. They also examined mood 
alterations with the Visual Analogue Scale. After a 6.3 
mile run at 85 percent of maximum aerobic capacity, the 
subjects were able to tolerate more pain and were more 
euphoric. They estimated that the reduced pain sensitivity 
was equivalent to 10 mill !grams of morphine sulfate. 
Running and Beta-endorphln. Wamsley (Note 1) noted 
that exercise can el !cit the release of Beta-endorphln and 
that after a strenuous work-out runners had elevated clrcu-
lat Ing Beta-endorph In. The harder the work-out, the more 
Beta-endorphln released Into the bloodstream. While these 
blood levels were too low to be analgesic he postulated that 
Reta-endorphln levels most l lkely relate to the hormonal 
control of oplolds or may reflect the Increased activity of 
opioid-containing neurons In the brain. 
1 1 
Recent studies provide support for Wamsley's position. 
B~ta-endorphln does Indeed Increase In blood plasma after 
rJnn Ing. Farrel 1, Gates, Maksud, and Morgan (1982) found 
t,at 30 minute treadml 11 runs Increased the Beta-endorphln 
l~vels 2-5 times for 6 endurance athletes. Their review 
lidlcated that; while peripheral levels probably did not 
r~flect central nervous system levels (Rossler, et al., 
13 7 7) and Int ravenous I nfus I on of Beta-endorph In d Id not 
r~sult In behavior change (Catlin, Gorel lck, Gerner, Hui, & 
L I , 1980), other studies have suggested that exerclse may 
s:lmulate a general stress response that results In In-
creased pituitary secretion of ACTH and Beta-endorphln Into 
pe ripheral venous blood (Gulllemln, Vargo, Rossler, Minick, 
Li ng, Rlvler, Vale, & Bloom, 1977; Rossler et al, 1977). 
Trie results agree with another study which Indicated exer-
c i se as a stimulus to the hypothalamic/anterior pituitary 
a x is (Colt., Wardlow., & Frantz., 1981). 
Summary. Opiate addiction., as described by medical 
l i terature does correspond to distance running addiction as 
reported in popular running 1 lterature and research. Opiate 
usage produces euphoria and analgesia as does distance 
running. Chronic usage of opiates and regular distance 
runn Ing produce dependency and to 1 e ranee wh I 1 e abs t I nence 
p r oduces withdrawal symptoms. A 1 a rge percentage of these 
symptoms appear to correspond; l r r I tab I 1 I t y., I n s omn I a., 
stomach upset (I.e. nausea), apathy and depression (I.e. 
pessimism)., muscle tension and soreness (I.e. spasms and 
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aches), restlessness, plus fatigue and physical sluggishness 
(I.e. feelings of weakness). The research Indicates that 
Beta-endorphln Is an endogenous opiate with analgesic and 
addictive properties which Is secreted by the pituitary 
gland and released into the blood In response to the stress 
of running. 
Psychopathology and Running 
Schizophrenia 
Naloxone research. Emrich, Cording, Plree, Koll Ing, 
Moller, von Zerrsen, and Herz (1979) and Vereby et al. 
(1978) reviewed research which utll !zed the morphine antago-
nist naloxone In psychotic patients. The possibility of 
therapeutic action of naloxone was raised by the discovery 
of Increased levels of CSF endorphins In chronic schizo-
phrenic patients (Terenlus, Wahlstrom, & Agren, 1977). They 
hypothesized that Increased endorphln levels by naloxone 
were impl lcated In the pathophyslology of psychoses. Gunne, 
Lindstrom, & Terenlus, 1977) further Investigated the possi-
ble antipsychotlc effect of naloxone In a single-blind study 
of six chronic schizophrenics. They reported Immediate 
reversal of auditory hallucinations In four patients after 
l.v. Injection of 0.4 mg. of naloxone. Several experiments 
which attempted to repl lcate naloxone's antlpsychotlc action 
on schizophrenics have yielded negative results (Volavka., 
Mall ya, Ba I g., & Perez-Cruet, 1977; Davis, Bunney, de 
Fraltes, Kleiman, van Kammen, Post., & Wyatt, 1977). Gunne 
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and Terenlus (1978) themselves were unable to repl lcate 
their own finding when they employed a double-blind design. 
Naloxone doses for this group of studies ranged between 0.4 
- 10 mg. and most patients received no more than 1.2 mg. per 
dose (Vereby et al., 1978). 
A second series of studies utll ized higher naloxone 
doses and an extended psychological rating period. Berger, 
Watson, Akll, & Barchas (1979), utilized 10.0 mg. doses of 
naloxone and reported s I gn If I cant reduct l on of ha 11 uc i na-
tions In 11 chronic schizophrenic patients. In their study 
psycholo g ical ratings were extended to 4 hours, as compared 
to the one hour duration fo r previous studies ( Volavka et 
al., 1977; Davis et al., 1977; Janowsky, Segal, Abrams , 
Bloom, & Guillemln, 1977). Emrich, Cording, Plree, Koll Ing, 
von Zerssen, and Herz (1977) also utll !zed an extended 
rating duration (up to 6 hours). They utll lzed 4.0 mg . of 
naloxone In a 20 subject study and reported naloxone-lnduced 
reduct I on In sch i zophren I c ha 11 uc I nat Ions. Emrich et al. 
( 1979) replicated the study utilizing a still higher dosage 
of naloxone (24.8 mg.). They reported that the higher 
do sage was no more effect Ive than the 4. 0 mg. dosage of 
naloxone. They concluded that 4.0 mg. of naloxone may have 
a smal 1 anti-psychotic effect on schizophrenic halluci-
nations but Is not effective as a short-acting treatment. 
In summary, Vereby et al. (1978) suggests that cl lnlcal 
t erapeutlc experiments using naloxone administered Intra-
venous 1 y a re d I ff I cu 1 t to conduct and Interpret. Patients 
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must exhibit psychopathology at the time of administration 
so that a therapeutic effect Is observable. Those patients 
who show signs of psychosis practically a11 the time "are 
rather rare and In no way representative of the schizo-
p h re n I c pop u 1 at I on" ( p . 8 8 2 ) • A 1 so, Int ravenous I nJ ect Ions 
ca n have a placebo effect which can distort even the 
placebo-control led experiments. Studies utl1 !zing orally 
ad~lnlstered antagonist (na1trexone) reported no therapeutic 
effect on schizophrenics (Mielke & Gallant, 1977; Gunne & 
Te re n I us , 1 9 7 9 ) . Ve re by et a 1 • , ( 1 9 7 8 ) fur t he r states t hat : 
experiments with opiate antagonists have provided 
1 lmlted support for the hypothesis of endorphin 
excess [In schizophrenia] and no support for the 
hypothesis of endorphln defic i ency. While the 
na1oxone doses used In many studies was probably 
too low , there may be a subgroup of psychiatric 
patients who do have an Important disturbance of 
the endorphln system. (p. 883). 
Beta-endorphln research. Vereby et al., 0978) also 
reviewed Beta-endorphin research on schizophrenia. Interest 
In the possible role of Beta-endorphln In schizophrenia was 
Initiated by the findings of two studies which observed that 
lntracerebral administration of Beta-endorphln el !cited 
r i g I d I mmo b I 1 I t y I n rat s w h I c h w a s rev e rs I b 1 e by n a 1 ox one 
(Bloom et a1., 1976; Segal, Browne, Arnsten, Bloom, Davis, 
Gul11emln, & Ling, 1979). 
15 
Kline and associates (Kline & Lehmann., J97Q; Kline., LI., 
Lehmann., Lajtha., Laski., & Cooper., 1977) have done cl lnlcal 
testing of Beta-endorphin. They administered single i.v. 
injections of Beta-endorphin (10.0 mg. maximal) on a total 
of 15 patients with various psychiatric diagnosis. Improve-
ment of schizophrenic (and depressive) symptoms was report-
ed. Vereby et al . ., (1978) expressed that caution should be 
utilized in interpreting these results. Since no active 
placebo was used and the first effects of Beta-endorphin 
(I.e. feel Ing of warmth and dry mouth) occurred within 
minutes after the injection., It Isl lkely that patients were 
aware that they were receiving an active substance. Also, 
unstructured i nterv I ews were conducted by the authors, who 
knew what was administered. 
In addition to the review by Verehey et al. (1978) two 
double-bl ind, placebo-controlled studies., which administered 
Beta-endorphln i • V. to schizophrenic patients, reported 
d I s c re pan t f I n d I n g s . Be r g e r , v-/ a t son , A k I 1 , E 1 1 I o t t ., R uh i n , 
Pfefferbaum, Davis., Burchas., & LI (1980) administered weekly 
injections of Beta-endorphins (20.0 mg.) to 10 male schizo-
phrenics. They reported a statistically significant but not 
cl lnlcal ly apparent., decrease In schizophrenic symptoms 
utilizing the Brief Psychiatric Rating Scale (BPRS). 
Gerner., Cat 1 in., Gorel lck, Hui., and LI (1980) reported that 6 
of 8 schizophrenic patients became more uncommunicative and 
wl thdrawn, as determined by cl ln!cal ratings and the BPRS, 
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~o · lowing Beta-endorphin Injections of 1.5 to 11.5 mg. 
Summary. The inconsistent findings of naloxone and 
Beta-endorphln 
clear role for 
phrenlcs. It 
research In schizophrenia do not delineate a 
Beta-endorphln In the treatment of schizo-
appears that Beta-endorphin (In excess) may 
ha ve a 1 imlted, as yet, undefined role In the treatment of a 
subpopulation of schizophrenics. 
Mania and Depression 
Naloxone research on mania. Judd and Janowsky (1981 ) 
anc Emrich (1982) have reviewed the research on the anti-
man i a p rope rt I es of n a l ox one • Two stud I es by Se g a l and 
co llegues originally suggested that naloxone might have 
a11tlma nia properties . Segal, Brown, Bloom, Gulllemln, and 
Ling (1977) reported that low dose opioid peptides and 
oo I a t e s i n du c e d a n a l ox one - rev e rs I b l e be ha v I o r a 1 a c t I v a t I on 
11 rats. Segal et al., (1979) also found that naloxone 
a1tagonlzes a stimulant Induced activation. 
Two studies cl lnlcally tested naloxone on mania. 
D:ivls, Runney, Bucksbaum, de Fraltes, Duncan, Gillins, van 
K:immen, Kleinman, Murphy, Post, Reus, and Wyatt (1979) 
r~ported a therapeutic effect In 1 out of 4 manic pat tents 
U3 i ng 10.0-30.0 mg. naloxone. Janowsky, Judd, Huey, 
R)itman, Parker, and Segal (1978) also reported antimanlc 
e~fects in 12 manic patients with 20 mg. of naloxone. 
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In contrast., two studies observed no changes In manic 
patients with naloxone treatment. Emrich et al. (1979) 
treated two manics with 4.0 naloxone while Davis, Exteln., 
Reus., Hamilton., Post., Goodwin., and Bunney (1980) utll !zed 20 
mg. on 10 patients and found no significant changes. Emrich 
1982) in summarizing his review suggests that the anti-manic 
effect of naloxone appears questionable. 
Naloxone and 
Emrich (1982)., In 
minimal Influence 
Beta-endorphln 
his review., 
of na 1 ox one on 
research on depression. 
reported the apparently 
depress I on based on the 
findings of three studies. Emrich., et al • ., (1979) found a 
tendency towards deterioration ln 3 patients with endogenous 
depression treated with 4.0 mg. of naloxone. Terenlus., 
Wahlstrom, & Agren (1977)., In 5 patients., observed no 
significant changes during a 6-12 day treatment with 0.4-0.8 
mg. of naloxone. 
al. (1979). 
Similar findings were reported by Davis et 
Davis., In (Bunney et al • ., 1979)., Judd and Janowsky 
(1981) and Emrich (1982) reviewed the research on Beta-
endorphln and depression. Kl lne et al. (1977)., In an open 
study., found that 1. 5-6. 0 mg. of Beta-endorph In I. v. pro-
duced be n e f I c I a 1 effect s I n two depressed pat I en ts . K 1 I n e 
and Lehman (1979) summarized their cl lnlcal testing of 
Beta-endorphln of 15 patients with various psychiatric 
diagnoses Including depression. They report that acute 
administration of Beta-endorphln (6.0 - 10.0 mg.) produced 
persistent. Improvements In the symptoms of depression. As 
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reported In the schizophrenia section of this paper, Vereby 
et al. (1978) noted that these results requl red repl !cat Ion 
utll izing a double-bl Ind design and controll Ing for the 
I mm e d I a t e e f f e ct s of Bet a - end o r p h I n ad m I n I s t e red by I n j e c -
tlon (I.e. feel Ing of warmth and dry mouth). 
Further research control led for the Inject Ion effects 
of Beta-endorphln and utilized a double-blind design. 
Angst, Autenrleth, Brem, Koukkou, Meyer, Stassen, and Storck 
(1979) administered Beta-endorphln In a slow Infusion rather 
than by Injection. They observed a switch to hypomanla/ 
manla In 4 of 6 depressed patients with 10.0 mg. of Beta-
endorphln. Two more recent studies (Gerner et al, 1980; 
Gorel !ck, Catl In, & Gerner, 1981) used a double-bl lnd design 
and administered 1.5-11.5 mg. of Beta-endorphln by Infu-
sions. They found antldepresslve e~fects for 8 of 10 
depressed pat I ents as measured 
al., (1981) additionally found 
later responded at higher doses. 
by the 
that 2 
BPRS. Gorel !ck et 
depressed subjects 
This finding could Ind!-
cate that there "may be a dose threshold for response to 
Beta-endorphln." (p. 241). Emrich (1982), In his review, 
cone 1 uded that the re Is ev I dence that Beta-endorph In has 
curative effects In depression. 
Summary • Conf 1 I cted f Ind I ngs on the ant I man I c effect 
of the antagonist naloxone have establ !shed no clear pattern 
for Its therapeutic use In manic patients. Research with 
naloxone on the treatment of depressed patients has yielded 
either sl lght deterioration or no change. Beta-endorphln 
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treatment, by slow Infusion, has demonstrated a clear thera-
peutic effect on depressive patients. 
Pain 
Chronic pain. Davis, In Bunney et al. (1979), and 
Terenlus (1981) provided reviews of the research on Beta-
endorph In and pa In. Bushsbaum, Dav Is, and Bunney C 19 7 7) 
reported that naloxone caused measurable, but cl lnlcally 
Insignificant, hyperanalgesla In 
study, utilizing normal subJects, 
normal subjects. Another 
observed an Increase in 
reported acute post-surgical dental pain with naloxone 
administration (Levine, Gordon, Jones, & Fields, 1978). 
Research by Almay and associates (Almay, Johansson, von 
Knorrlng., Sedvall., & Terenlus., 1980) reported that patients 
with organic pain have slgnlflcantly lower endorphln levels 
than patients with pain of psychogenic origin. Further 
support for the role of Beta-endorphln In pain was found In 
two studies which reported that intraventrlcular and intra-
venous administration produced pain rel lef In patlents 
suffering from chronic Intractable pain (Catl In, Hui, & Loh, 
1977; Hosobuchl & LI., 1978). 
Migraines. Terenlus (1981) reviewed the research on 
endorphins and 
Anselmi (1979), 
withdrawal on 
migraine pain. 
from a study 
serotonin and 
between a classic migraine 
Slcuterl, del Blanco, & 
of the effects of morph I ne 
dopamine, noted a similarity 
attack and the morphine abst I-
nence syndrome. They concluded that migraines may be caused 
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by disturbances in the endogenous analgesic mechanism. 
Additional support Is contributed by a study which measured 
endorphln levels in CSF of 7 male and female headache 
patients (Sicuterl, Anselmi, Curradl, Mlchelaccl, & Sass!, 
1978). They found lower endorphln levels In the presence of 
headache pain and elevated levels (3-4 times) In the absence 
of pain. Slcuterl, Anselmi, and del Blanco (1978) proposed 
that migraine pain depends on the variation In endorphln 
activity and that the attack ts precipitated by a sudden 
drop ln endorphin activity. Terenlus (1981) concluded that 
this hypothesis for a mechanism of migraine should be 
possible to test experimentally. 
Summary. Ch ron I c pa In and Beta-endo rph In research to 
date has Indicated that Beta-endorphln does provide relief 
for chronic pain. Further research utll !zing Beta-endorphln 
specifically has not been done. Research does suggest that 
an Increase In Beta-endorphln levels might be therapeutic 
for migraine pain. 
Stress/Anxiety 
An I ma l research. As noted by Naber, Bullinger, Zahn, 
Johnson, Huhtanleml, Pickar, Cohen, and Bunney (1981), 
animal studies have Indicated a stress-Induced Increase of 
Beta-endorphln secretion (Rossler et al., 1977; Gulllemln et 
al., 1977). An additional study, using rats, found that 
plasma Beta-endorphln levels vary In response to different 
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physical stressors and may reflect the degree of stress 
experienced (Mueller, 1981). 
Human research. The effect of Beta-endorphin on stress 
In humans has not yet been demonstrated to date (Naber et 
al., 1981). Naber et al. (1981) Investigated the effects of 
three stressors, (an attentional, a cognitive and a physical 
task) on Beta-endorphln blood levels and opioid activity In 
relationship to psychophyslologlcal and psychological 
v a r I ab l es • F r om t h I s stud y o f 1 2 sub j e ct s t hey con c 1 u de d 
that neuroendocrlne response parallels psychophysical 
arousal and ls dependent on stressor quality as well as 
Individual personal lty differences. They also reported that 
n e I the r Bet a - end or p h I n 1 eve l s nor op I o I d act I v I t y sh owed a 
significant stress effect. The authors question whether the 
endophlnerglc systems were susceptible to the emotional or 
slight physical stressors utll lzed In this study. 
Tn summation, there ls animal research Indicating that 
Beta-endorphln secretion Increases In response to stress but 
there ls minimal and non-supportive human research on this 
hypothes Is. Further research Is requ I red and as suggested 
by Naber et al. (1981) more stressful situations may yield 
marked changes. 
Running Therapy 
Depression. The reviews by Jacobs (1981), Wieman 
(1980), and Sacks and Sacks (1981) were used to examine the 
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research regarding running as a treatment for depression. 
Morgan, Roberts, Rrand, and Felnerman (1970) researched the 
psychological effects of chronic physical activity on 67 
male subjects. They compared adult males pa rt I c I pat Ing In 
exerc I se programs wl th a sedentary control group. While 
they found that exercise did not significantly reduce 
depression scores for the entire treatment group, 11 depres-
sed subjects showed significant Improvement. 
Two correlation studies support the Idea that depres-
sion changes as a result of physical fitness (Folkins, 
Lynch, & Gardner, 
1975 ) . Folkins 
1972; Kavanaugh, Shepard, Tuck, & Qureshi, 
et al . (1972), In a study of students In 
jogging classes compared to golf and archery classes, 
reported that for women joggers an Improvement In depression 
scores correlated significantly with Increased physical 
fitness. Kavanaugh et al. (1985) studied male, depressed, 
postcoronary patients. Subjects who compl led with the 
exercise-based rehabilitation program demonstrated a sign!-
flcant improvement 
d I d not comp l y at 
significant change 
In their depression scores. Subjects who 
least 60 percent of the t !me showed no 
In depression. Folkins (1976), using 
subjects Identified as high risk for coronary disease, found 
that a 12-week exercise program significantly Improved 
depression scores. A study which compared the effects on 
depression In a variety of exercise groups with a non-
exercising control group reported that; all exercise groups 
(with the exception of softball) showed some reduction In 
23 
depression and that Jogging reported the greatest decrease 
while the control group showed no reduction (Brown, Ramirez, 
& Taub, 1978). Wieman (1980) in a study which attempted to 
account for the reduction In depression associated with 
runn Ing found that Joggers reduced the Ir depress I on more 
than racketball players. 
Running as an actual treatment for depression has been 
examined In a series of studies by Griest and associates 
(Sacks and Sacks, 1981). In a pilot study of 28 depressed 
male and female patients, Griest, Klein, Eischens, and Faris 
(1978), reported that running as a treatment was as 
effective In alleviating depressive symptoms as either 10 
weeks of time-limited or time-unlimited psychotherapy. A 
subsequent study by Griest et al. (1978), which utl 1 lzed a 
higher criteria for depressive symptoms, found greater 
levels of Improvement for the running and time-limited (12 
weeks) treatment groups than the tlme-unl lmlted treatment 
group. Griest, Eischens, Klein, and Linn (Sacks and Sacks, 
1981), In two studies which were plagued bv high drop out 
rates, treated a total of 60 subjects. They reported that 
group runn Ing reduced depress Ive symptomo 1 ogy, wh 11 e group 
meditation and group psychotherapy failed to significantly 
reduce depression. A 
depression In 4 women 
study by Doyne (1981) on cl lnlcal 
patients found greater decreases In 
depression during the aerobic exercise phase than during the 
attention-placebo phase. She concluded that aerobic 
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exercise was an effective and active treatment for 
clinically depressed women. 
Colt, Dunner, Hall, and Fleve (Sacks and Sacks, 1981), 
reported that 22 female runners had a higher prevalence of 
affective disorder than norms. In male runners the preva-
lence of affective disorders was non-significant as compared 
to male controls but In the same direction as female run-
ners. 
In summary, research on running as a treatment for 
depresslon has supported the therapeutlc effect of running 
for both male and female depressives. This therapeutic 
effect appears to be as powe rfu 1 as psychotherapy In the 
treatment of depresslon. Limited evidence has Indicated 
that runners (especlally female runners) are also more 
1 lkely to have an affectlve dlsorder. 
Anxiety/Stress. Three reviews were utll lzed to examine 
the research on running as a treatment for anxlety (Jones, 
1981; Jacobs, 1981; Sacks and Sacks, 1981). A primary 
Investigator In the relatlonshlp between acute physlcal 
exerclse and tenslon/anxlety reduction has been W. P. 
Morgan. An early study by Morgan, Roberts, and Fe I nerman 
0970), tested the effects on anxiety of treadmill walklng 
(one mile at 3.5 mph) for 36 male subjects. The results 
Indicated no slgnlflcant difference In anxiety between the 
three groups; 3.5 mps/zero percent grade, 3.5 mph/five 
percent grade, and a control group which rested. The 
authors proposed that the exerclse was not vlgorous enough 
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to demonstrate an effect and the TPAT Anxiety Battery was 
not sens It Ive enough to detect the changes Incurred by the 
treatments. 
Further research which utll !zed more Intensive physical 
exertion and other anxiety measures reported results which 
are In contrast to Morgan et al. (1970). Research by 
F o l k I n s et a 1 • C 1 9 7 2 ) comp a red two g r o ups of st u dent s for 
one school semester. Post-test anxiety was decreased for the 
Intense sport activity group but not 
group. A later study by Morgan (1973) 
state anxiety 20-30 minutes after a 
physical workout as compared to pre 
the light recreation 
found a decrease In 
45-mlnute, vigorous 
and i mm e d I a t e l y po s t 
measures. These findings were replicated by Morgan (1973) 
in a second study of 15 male subjects. The anxiety measure, 
the State-Trait Anxiety Inventory 
before, five minutes after, and 
vigorous run of 15 minutes duration. 
(STAI), was completed 
20-30 minutes after a 
Significant decreases 
In anxiety were reported for both post-exercis~ tests. 
Morgan and Horstman (1976) In a series of studies, 
investigated 177 adult males and 38 adult females. Subjects 
were required to expend 80 percent of their aerobic power 
and anxiety was measured by a modified form of the STAI. 
In the first four experiments, state anxiety was 
found to consistently decrease 70 to 30 minutes 
following the exercise. [In the latter experiments 
It was found that] state anxiety Increased during 
the early exercise; reached an asymptote about 
halfway through the exercise, and then decreased 
rapidly following exercise. (p. 62). 
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Bahrke and Morgan In Sacks and Sacks (1981), reported 
that for regular exercisers acute physical activity reduced 
state anxiety while meditation and quiet rest did not. 
Jones (1981) investigated the effects of aerobic 
exercise; anaerobic exercise, and meditation on stress for 
85 college students. Subjects were administered the STAI, 
the Cognitive Somatic Anxiety Questionnaire and The Physical 
Symptoms Checkl 1st before and after the semester. Subjects 
In the aerobic exercise group showed significant decreases 
In both somatic and cognitive anxiety while anaerobic group 
subjects decreased only In somatic anxiety. The aerobic 
group reported a decrease In trait anxiety while the anaer-
obic group Increased In state anxiety. No significant 
changes were reported on the physical symptoms checkl 1st for 
either of the exercise groups. The results of th Is study 
Indicated that aerobic exercise reduced trait, somatic, and 
cognitive anxiety. 
Running as a specific treatment for anxiety reduction 
was Investigated In two studies. Lion 0978) administered 
the STAI to six psychiatric patients before and after a 
two-month program of running/walking one mile for three 
times per week. The results demonstrated a significant 
decrease In anxiety for the treatment group. Dienstbler, 
Crabbe, Johnson, Thorland, Jorgensen, Sadar, and LaVel le 
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(Sacks and Sacks, 1981) studied the effects of moderate and 
marathon running on stress tolerance. They reported that 
both moderate and marathon running reduced anxiety and 
positively Influenced tolerance for subsequently Introduced 
stress for the 23 subject runners. 
Summary. Research on v I gorous phys I ca 1 exe re I se and 
running have Indicated that state anxiety, for both males 
and females, Is decreased following as 1 lttle as 15 minutes 
of exercise. Regular vigorous aerobic exercise as Indicated 
by one study, may also result In decreased trait, somatic.,. 
and cognitive anxiety. Regular running at both moderate and 
marathon levels has been reported to Increase stress 
tolerance. 
Personal lty Change and Running 
Introversion and emotional stability. Three author's 
reviews of the research on distance running In relation to 
personal lty were examined (Chan.,. 1981; Nakagaua.,. 1981; 
Jacobs, 1981). Two of these studies (Chan, 1981; Jacobs, 
1981) concluded that distance runners, as a group, tend more 
toward Introversion. Cl ltsome and Kostrubala (1977), using 
the Myers-Brigg Type Indicator, reported an extrovert-
Introvert ratio of 1:1 in 100 marathoners. This ratio 
differs from the 3:1 extrovert-Introvert distribution found 
In the general population of the United States (Chan, 1981). 
Jacobs (1981), In his conclusion, suggested that It Is 
possible for Individuals to shift along the continuum of 
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extroversion-Introversion as a direct consequence of their 
involvement In runn Ing. Chan (1981) differs In her conclu-
slon, and suggests that "running does not alter an Individu-
al's personal lty structure; rather, certain Individuals who 
possess traits adaptable to the sport of running seem 
attracted to It" (p. 38). Nakagawa (1981) did not review 
the more recent studies on Introversion. Based on Morgan 
and Cost Ill's (1972) non-significant findings, Nakagawa 
reports that distance runners are within normal l lmlts for 
adults In Introversion. 
Both Chan (1981) and Nakagawa (1981) concluded that 
distance runners were characterized by somewhat greater 
emotional stabll lty (I.e. did not evidence neurotic Ism). 
Jacob's C 1981) rev I ew on self-concept and d I stance runn Ing 
did not contain research relevant to emotional stabll lty. 
In summary, the research on distance running and 
personal tty change appears to confirm that distance runners 
tend to be more Introverted as well as more emotionally 
stable than the general population. Research Is confl feted 
and minimal regarding personal lty change produced by 
running. 
Conclusions 
Addiction and Running 
A synthesis of the research on opiates, Beta-endorphln, 
and running provides an answer to: 
Question 1: Is distance running addictive and If 
so, what Is the role of Beta-endorphln tn this 
addiction? 
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Research Indicates that the propert les of the endo-
genous op I ate Beta-endorph In correspond to those of other 
oplolds. Usage produces euphoria and analgesia, while 
chronic use results In dependence and tolerance. Abstinence 
results In withdrawal symptomology which Include; Irritabil-
ity, Insomnia, nausea, apathy/depression, muscle ten-
sion/soreness, restlessness, and fatigue. It appears that 
Beta-endorph In Is secreted by the p I tu I ta ry gland and It is 
produced In response to the stress of running. 
Psychopathology and Running 
An Integration and summary of the research on naloxone 
and Beta-endorphln In psychopathology, use of running as 
therapy, and the personal !ties of runners provides the 
Information to answer: 
Question 2: What lmpl !cations would running pro-
duced Beta-endorphln have for therapy? 
Four areas of psychopathology were examined for possi-
ble effects of Beta-endorphln. In schizophrenia the re-
search Indicates that there may be a subpopulation of 
schizophrenics who have an excess of Beta-endorphins which 
Is reversible by naloxone treatment. The research on mania 
and depression report confl lcted findings for the antlmanlc 
effect of naloxone but Indicate a clear therapeutic effect 
for Beta-endorphln on depression. Beta-endorphln produces 
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pain rel lef In chronic pain and may possibly be therapeutic 
In migraine patn. There Is mlntmal and non-supportive 
research on the effect of Beta-endorphln on stress/anxtety 
In humans, though animal research Indicates that secretion 
does increase In response to stress. 
Running as therapy has been explored tn connection with 
the treatment of depression and stress/anxiety reduction. 
There appears to be support for the therapeut le effect of 
running on depression and state anxiety. 
Evidence regarding the potential for personal lty change 
from running Is contradictory and Inconclusive but the 
research does report that runners tend to be more Introvert-
ed and emotionally stable than the general populatton. 
Discussion 
A major concern of this paper was to provtde lnforma-
t Ion for the pract It loner. Tow a rd th Is end research data 
was gathered and combined from such diverse research areas 
as; animal and human physiology, addiction, psychopathology, 
and personal tty, as wel 1 as, popular runntng 1 lterature. Of 
primary Import for the practitioner Is that running as an 
adjunct or even an al ternat Ive treatment to psychotherapy 
for depression appears to have foundatton. Some runners may 
ut 11 I ze runn Ing as a means of se 1 f-med I cat I on for the Ir 
depression. It Is possible that runners may self-treat 
their anxiety In a similar fashion. Running therapy for the 
treatment of anxiety does seem to have some basis. 
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According to popular l lterature, the threshold of 
running addiction Is approximately 40 minutes of running per 
day, pursued for a period of one year. In view of; the 
relative accessabll lty of this addiction, the popularity of 
running, plus its Impact on depression and anxiety, the 
probability Is high that the practitioner will deal with 
running, In some aspect, In a patient. A practitioner might 
treat a depressive or anxiety prone runner or possibly an 
addicted runner suffering the withdrawal symptoms from 
runn Ing abs t I nence. Recogn It I on of the psycho 1 og I ca 1 
effects of running and physiological etiology of running 
addiction would aid In the diagnosis and treatment of 
runners. The practitioner also may treat the negatively 
add lcted runner whose "need to" run has adversely Impacted 
his social environment, mental and/or physical health. It 
Is even possible that In the future, specific dosages of 
running or Beta-endorphln may be prescribed for depression 
and anxiety. 
Future Research 
The second major cons I de rat I on of th Is paper was to 
develop a foundation of knowledge from which to extrapolate 
areas for future research. 
Specific recommendations for future research arose from 
the area of physiology. To date, the c 1 osest approach to 
measurement of Central Nervous System Beta-endorphln activi-
ty Is by analysis of concentrations in Cerebrosplnal fluid. 
Repeated sampl Ing I s difficult to Justify 
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ethically 
(Terenlus, 1981). Beta-endorphln Is produced In the pitui-
tary, outside of the blood-brain barrier. ~Jhat then Is the 
relationship between blood Beta-endorphln levels, which are 
too low to account for physiologic effects, and pituitary 
Beta-endorphin (Wamsley, Note 1). 
Pert In Bunney et al. (1979) noted that causal lty 
between analgesia and Beta-endorphln would require a demon-
stration that Beta-endorphln Is released In those brain 
regions that mediate analgesia during the analgesic manipu-
lation. Bunney et al. (1979) concluded that the lack of 
understanding of the mechanism of addiction remains a major 
unsolved problem. Other quest Ions rema In unanswered., such 
as; what Beta-endorphln dosage and how much usage Is neces-
sary to produce and maintain addiction as well as what 
amount of Beta-endorphln Is produced by various degrees of 
running. 
The research on running and treatment point toward more 
areas of future research In depression and anxiety. While 
distance running Is therapeutic for depression, this gives 
rise to additional questions such as; how much running Is 
required to produce a therapeutic result, 
dose-response 
practitioner 
curve 
Involve 
for Beta-endorphln, 
a depressed pat I ent In 
ls there a 
how does a 
running, and 
does running actually prevent depression. In anxiety/stress 
research, ls the apparent non-support of human research with 
Beta-endorphln due to the use of sl lght emotional or 
physical stressors (Naber et al., 1981). 
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The apparent 
conf 1 I ct be tween research on human anx I et y, an I ma 1 research 
and running as a treatment for anxiety awaits an explana-
tlon. A final factor In the research on the running treat-
ment of both depression and anxiety Is the ethical consider-
ations Inherent In the utilization of an addictive drug on 
human subjects. 
Finally, current research has not clearly demonstrated 
a one-to one correspondence between opiate and running 
addiction withdrawal. Research In this area may prove 
difficult. An Indication of this difficulty occurs In a 
study by Baekeland (1970) In which regular runners refused 
to be deprived of their exercise despite monetary rewards 
offered for part lclpat Ion In the study. Even If runners 
were to voluntarily abstain from running or were unable to 
run, they could constitute a biased sample. 
The posslbil ltles for future research extend beyond 
those ennumerated In this section and beyond even the scope 
of this paper. It remains to be known what the complete 
ramifications of the dramatic rise In the popularity of 
running has upon the physiology and psychology of those who 
run. 
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